Posted on

HGH Fragment 176-191 Weight Loss Results

HGH Fragment 176-191 Weight loss results in research are interesting. hgh fragment 176-191 weight loss results The HGH fragment (176-191) is a synthetic peptide that represents the short specific portion of the amino acid chain of HGH (amino acids at positions 176-191 at the C-terminus of the human growth hormone). Just this fragment of HGH is responsible for its strong fat-burning properties but does not have a strong impact on insulin levels as HGH does.

HGH Fragment 176-191 Dosage 5mg Results

In order to be able to use this peptide for the treatment of obesity and type 2 diabetes, various research teams have spent time, money, and effort trying to develop a more potent short HGH peptide. So it has been found that fragments with a length of 10 to 15 amino acids or their combination with fragments of the sequence corresponding to positions 176-191.

How Effective is the HGH fragment?

In the sequence of the HGH, it has a significant effect on glycemic control. It is generally accepted that a short peptide can bind to the HGH receptor. However, it is a well-known fact that some receptor binding is also dependent on the presence of the whole protein. The short fragment of the HGH is also very important in regard to its stability. It is a known fact that after degradation of the N-terminal sequence (amino acids 1-29) of the hormone the HGH fragment has a half-life of about 10 minutes.

HGH Fragment 176-191 vs HGH

A short fragment of HGH can be used alone or in combination with HGH. Although most of the effects of the short fragment of HGH in vivo, e.g., fat loss, are observed when the molecule is given orally or by injection in a single dose. It is also possible to achieve an increase in the levels of insulin and other hormones after repeated administration. The short fragment of the HGH can also be obtained by peptide synthesis and has a strong and lasting effect. It can be used in the treatment of obesity or in the treatment of the symptoms of diabetes.

How long does it take HGH FRAG to work?

It was established that when the short HGH fragment is administered to humans it produces an increase in insulin sensitivity, which is not achieved in its application in the same dose when it is given in combination with HGH (SEQ ID NO: 1-8). According to one particular embodiment of the invention, a mixture of two peptides is produced which contains the short fragment of HGH (amino acids 176-191), and the sequence of this peptide is not identical to any sequences which are already known in the literature.

These known peptides are listed in U.S. Pat. No. 6,410,819, issued Jul. 2, 2002; JP 10265969, published Sep. 11, 1998. The novel peptide is an HGH fragment of about 15 to 25 amino acid residues, preferably 20 amino acid residues.  Mostly the 23 amino acid residues at the N-terminus is added to an amino acid sequence of the C-terminus of the short fragment of HGH of about 10 to 20 amino acid residues. It is about 15 amino to 19 amino acid residues.

How many units of HGH Frag should I take?

Preferably, the mixture of these peptides is injected subcutaneously, intradermally, intravenously, or by other appropriate injection means into a patient in need of such treatment. The short HGH fragment can be obtained by chemical synthesis, preferably by solid-phase peptide synthesis, using amino acids methionine and cysteine.

Pepgen (a trading name for this particular peptide), produced by Alvine Laboratories Inc., Alvine, NJ, USA is an example of a peptide that may be used according to the invention. It is a peptide that contains 10 amino acids from the C-terminal region of HGH (amino acids 176-191) with cysteine at position 177.

HGH Fragment 176-191 Weight Loss Results

This peptide can be administered to animals (including humans) in an amount sufficient to achieve the desired effect of reducing body fat and/or preventing fat from being stored. Pepgen was tested in the field of obesity treatment.

One form of this invention is to deliver the peptide to patients at need in the form of a depot composition. The depot composition comprises the peptide and a biocompatible, biodegradable, non-toxic, solid biocompatible polymer, optionally in the form of a gel or microcapsule

To deliver the peptide to patients at need in the form of an injectable solution. As injectable solutions, the one skilled in the art will know suitable aqueous solutions such as saline or other acceptable aqueous solutions.

The invention is to deliver the peptide to patients at need in the form of a microparticulate. A suitable microparticulate has an average size from about 1 to about 500 microns, preferably from about 5 to about 250 microns.